Ontology highlight
ABSTRACT:
SUBMITTER: Cortes JE
PROVIDER: S-EPMC4979199 | biostudies-literature | 2012 Oct
REPOSITORIES: biostudies-literature
Cortes Jorge E JE Kim Dong-Wook DW Kantarjian Hagop M HM Brümmendorf Tim H TH Dyagil Irina I Griskevicius Laimonas L Malhotra Hemant H Powell Christine C Gogat Karïn K Countouriotis Athena M AM Gambacorti-Passerini Carlo C
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120904 28
<h4>Purpose</h4>Bosutinib is an oral Src/Abl tyrosine kinase inhibitor. The phase III Bosutinib Efficacy and Safety in Newly Diagnosed Chronic Myeloid Leukemia (BELA) trial compared bosutinib with imatinib in newly diagnosed, chronic-phase chronic myeloid leukemia (CML).<h4>Patients and methods</h4>A total of 502 patients were randomly assigned 1:1 to bosutinib 500 mg per day or imatinib 400 mg per day.<h4>Results</h4>The complete cytogenetic response (CCyR) rate at 12 months was not different f ...[more]